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1. INTRODUCTION 
___________________________________________________________________________ 
 
 
Depression is one of the most common psychiatric disorders in the general population, with a 
life-time prevalence of 24.2% in Hungary [1]. The affective disorders pose a very severe 
public health problem with their medical and psychosocial complications (e.g. suicide, 
disability, and secondary alcohol and drug abuse). The WHO reports on the global burden of 
disease have placed major depression fourth among the leading causes of disease burden in 
the developed regions of the world, and predicted that, after heart disease, it will become the 
second by the year 2020. 
The principal treatments of mood disorders are psychopharmacological and psychosocial 
therapies. During recent years, international trends have indicated a dramatic increase in the 
use of antidepressants, particularly after the introduction of selective serotonin reuptake 
inhibitors (SSRIs) in the early 1990s. Several other new classes of antidepressants have 
emerged over the last decade, which offer the possibility of treating patients with less toxic 
and more tolerable agents, thereby improving the compliance and possibly improving the 
outcome as compared with the “classical” tricyclic antidepressants (TCAs). Without adequate 
treatment, depression has the tendency to assume a chronic course, be recurrent, and over time 
to be associated with increasing disability. 
Suicidal behaviour is one of the most serious potential complications of depressive disorders. 
Psychological autopsy studies have shown that an affective disorder is present in 60% of 
suicides and a psychiatric disorder of some sort is present in approximately 90% of all 
suicides [2]. In recent years, considerable attention has been given to epidemiological studies 
that evaluated the association between increasing antidepressant consumption and decreasing 
suicide rates. 
Besides increased morbidity and disability rate, depression produces a significant decrement 
in the individuals’ health-related quality of life (HRQoL). 
A number of trends in health care have resulted in the development and growing use of 
patient-based outcome measures to assess matters such as the functional status and HRQoL. It 
is increasingly recognized that traditional biomedically defined outcomes such as clinical and 
laboratory measures need to be complemented by measures that focus on the patient’s 
concerns in order to evaluate interventions and identify more appropriate forms of health care. 
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Interest in patient-based measures has been fuelled by the increased importance of chronic 
conditions, where the objectives of interventions are to arrest or reverse a decline in function. 
Initially, psychiatrists showed hesitation regarding quality of life (QoL) assessment because 
the mainstream concept of QoL in medicine, with its emphasis on the subjective well-being 
and satisfaction of the patient, is less separated from psychiatric concepts of mental disorders 
than from medical concepts of somatic diseases. However, in the early 1980s, they came to 
the forefront of QoL research by conducting several studies on patients with chronic mental 
illnesses, such as depression. This has led to the introduction of a large number of instruments 
for assessment of the QoL [3]. 
The purpose of the present study was to apply pharmacoepidemiologic methods to investigate 
trends of antidepressant consumption in Hungary and its impact on suicide rates. Furthermore, 
I intended to develop the valid Hungarian version of a suitable depression-specific quality of 
life measure and to assess the health-related quality of life in depression with. 
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2. BACKGROUND 
___________________________________________________________________________ 
 
 
2.1. Drug utilization 
In order to work towards a more rational use of medication, it is essential to have accurate 
information on patterns of drug prescription and use. 
Drug utilization was defined by the WHO as an eclectic collection of descriptive and 
analytical methods for the quantification, understanding and evaluation of the process of the 
prescribing, dispensing and consumption of medicines and for the testing of interventions to 
enhance the quality of these processes [4]. 
The field of drug utilization research has attracted increasing interest since the 1960s. At a 
symposium in Oslo in 1969 entitled The Consumption of Drugs, the Drug Utilisation 
Research Group (DURG) was established and appointed with the aim of the development of 
internationally applicable drug utilization methods. In the mid-1970s, the Anatomical 
Therapeutic Chemical (ATC) classification system was developed by Norwegian researchers 
for the classification of medication, and the Defined Daily Dose (DDD) was introduced as the 
measurement unit to be used in drug utilization studies. The WHO Collaborating Centre for 
Drug Statistics Methodology was established in 1982, with the purpose of coordinating and 
improving the use of this ATC/DDD system. 
In the ATC classification system, drugs are divided into different groups according to the 
organ or system on which they act and their chemical, pharmacological and therapeutic 
properties. Drugs are classified in groups at five different levels. There are fourteen main 
groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th 
levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical 
substance. 
The structure of the code is illustrated by the complete classification of escitalopram: 
N  Nervous system 
  (1st level, anatomical main group) 
N06  Psychoanaleptics 
  (2nd level, therapeutic subgroup) 
N06A  Antidepressants 
  (3rd level, pharmacological subgroup) 
N06AB Selective serotonin reuptake inhibitors (SSRI
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  (4th level, pharmacological/chemical subgroup) 
N06AB10 Escitalopram 
  (5th level, chemical substance) 
The DDD is an internationally accepted technical unit in dug utilization studies. It means the 
assumed average maintenance dose per day for a drug used for its main indication in adults. 
Utilization is normally expressed as the number of DDDs/1000 inhabitants/day, which allows 
comparisons of drug use between countries, regions and other health-care settings. It also 
allows the evaluation of trends over time [5]. 
The number of drugs accounting for 90% of drug use (DU90%) may serve as an indicator of 
the quality of drug consumption. The method ranks drugs by volume of DDD and determines 
how many drugs account for the DU90% segment [5, 6]. 
 
2.2. Polypharmacy 
Polypharmacy is an important risk factor as concerns the initiation of complications arising 
from drug therapies (e.g. drug-drug interactions, adverse drug reactions, non-compliance, or a 
decrease in QoL). It also imposes a substantial financial burden on both the patient and the 
health-care system. 
The definition of polypharmacy in the literature is not uniform. There are basically two 
approaches to the definition. The first refers only to the number of drugs taken 
simultaneously. According to this, polypharmacy means the concurrent use of 2 or more 
drugs. However, some authors distinguish between minor polypharmacy (the concurrent use 
of 2 to 4 drugs) and major polypharmacy (the concurrent use of 5 or more drugs) [7-12]. 
The other approach to the definition focuses on the clinical indication and the effect of the 
administered medication. According to this definition, irrational, clinically not indicated drug 
use is regarded as polypharmacy [7, 13-15]. 
In the present study, the standard definition was used, and therefore the chronic and 
concurrent use of 5 or more medications was considered to be polypharmacy. 
 
2.3. Quality of life 
 
2.3.1. Definition 
The concept of QoL is not yet defined in a uniform way. However, the WHO 
conceptualization of health is employed by most researchers as the theoretical origin for their 
study of QoL as it is influenced by health and medical care. In its 1947 constitution, the WHO 
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declared that “health is a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity”. By extending the definition of health to include 
total well-being, traditional measures of morbidity and mortality became inadequate as the 
sole indicators of health [3]. 
 
Definition Author 
‘Quality of life is an individual’s perception of their position in life in 
the context of the culture and value system in which they live and in 
relation to their goals, expectations, standards and concerns.’ 
 
WHOQOL 
Group, 1993 
‘Quality of life refers to patients’ appraisal of and satisfaction with 
their current level of functioning as compared to what they perceive 
to be ideal.’ 
 
Cella and 
Tulsky, 1990  
‘Quality of life in clinical medicine represents the functional effect of 
an illness and its consequent therapy upon a patient, as perceived by 
the patient.’ 
 
Schipper et 
al., 1996 
‘Quality of life measures the difference or gap at a particular period 
of time, between the hopes and expectations of the individual and the 
individual’s experiences. 
 
Calman, 
1984 
‘Health-related quality of life refers to the level of well-being and 
satisfaction associated with an individual’s life and how this is 
affected by disease, accidents and treatments from the patient’s point 
of view.’ 
 
Lovatt, 1992 
‘Health-related quality of life is the value assigned to the duration of 
life as modified by the impairment, functional states, perception and 
social opportunities that are influenced by disease, injury, treatment 
or policy.’ 
Patrick and 
Erickson, 
1993 
  
Table 1. Illustration of the range of definitions of QoL [16] 
 
Although the definitions vary, the concept of QoL encompasses three overarching 
dimensions: 
 What a person is capable of doing (functional status) 
 Access to resources and opportunities to use these abilities to pursue interests 
 The sense of well-being 
The former two dimensions are often referred to as objective QoL and the third as subjective 
QoL. Within these overarching dimensions, certain life domains have been identified, such as 
health, family, social reactions, work, financial status and living conditions. QoL is thus a 
complex notion. Two perspectives can be identified to frame core issues regarding QoL 
assessment: The general QoL and the HRQoL framework. 
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The general QoL underlines the considerable research that has been done as regards the 
general population. The goal of this line of research involves the social perspective of the 
status and well-being of various groups of people and the values that they and their societies 
place upon various aspects of life experience. Such a perspective may provide insight into 
what people strive for, why they choose as they do, and how different societies and subgroups 
within a society fare, relative to other, in their life aspirations. Measures based on this 
approach typically cover functional status, access to resources and opportunities, and the 
sense of well-being across multiple aspects of life domains. 
Although a low income, a lack of freedom and poor social support may be relevant to health, 
there is a tendency to exclude such general aspects when dealing with QoL in terms of 
medical research and to focus directly on disease-related aspects of functional capacity and 
well-being. For this purpose, the term of HRQoL has been coined [3, 16]. 
 
2.3.2. Instruments for measuring HRQoL 
The aim of QoL measurement is to quantify the impact of both the clinical condition and 
treatment on the wider aspects of a patient’s life, by going beyond physician-dominated 
indicators of the patient’s progress. The instruments used to measure the HRQoL can be 
classified into generic measures, and disease-specific measures. 
Generic instruments are intended to capture a very broad range of aspects of health status and 
the consequences of illness and therefore to be relevant to a wide range of patient groups. The 
content of such questionnaires has been deliberately designed to be widely appropriate. 
Because of this, they permit comparisons across treatments for groups of patients with 
different groups, to assess comparative effectiveness. However, the most significant drawback 
of using generic instruments is their lack of sensitivity [16]. 
Most widely used generic instruments: 
 Sickness Impact Profile (SIP) [17-21] 
 SF-36 Health Survey (SF-36) [22-24] 
 EuroQol Instrument (EQ-5D) [25-27] 
 WHO Quality of Life Assessment Instrument (WHOQOL) [28, 29] 
 Nottingham Health Profile (NHP) [30, 31] 
 
Disease-specific instruments have been developed in order to provide the patient’s perception 
of a specific disease or health problem (Table 2). These measurements are more likely to 
detect important changes that occur over time in the particular disease studied. They are 
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intended to have a very relevant content for a specific disease, and therefore all of the items in 
the instrument should have been developed specifically to assess the particular health 
problem. 
 
Name of instrument Disease Reference 
Arthritis Impact Measurement Scales (AIMS) arthritis [32] 
Psoriatric Arthritis Quality of Life (PSAQoL) arthritis psoriatrica [33] 
Ankylosing Spondylitis Quality of Life 
(ASQoL) 
spondylitis ankylopoetica [34] 
Asthma Quality of Life Questionnaire asthma [35] 
Diabetes-specific QoL Scale (DSQOLS) diabetes mellitus [36] 
Functional Digestive Disorders Quality of Life 
(FDDQL) 
functional digestive 
disorder 
[37] 
Quality of Life in Epilepsy Inventory (QOLIE) epilepsy [38] 
  
Table 2. Examples for different disease-specific instruments 
 
2.3.3. Requirements of a QoL instrument 
The content of any QoL instrument must be perceived as relevant by the patients. This is 
achieved by deriving the content of the instrument directly from relevant patients. In this way, 
face and content validity are maximized, resulting in higher rates of completion [39]. 
Any QoL instrument must have good reliability. This is determined by the test-retest 
reliability (reproducibility) and internal consistency. Test-retest reliability is concerned with 
the extent to which scores on a measure can be replicated. It is expressed as a correlation 
coefficient, with values in excess of 0.85 generally considered to indicate adequate reliability. 
The internal consistency of an instrument is an estimate of the degree to which its constituent 
items in a scale are interrelated. It means that individual items should correlate highly with 
each other and with the summed score of the total of items in the same scale. Internal 
consistency is generally assessed by using Cronbach’s α. An α value of 0.85 or above is 
indicative of adequate internal consistency [16]. 
All instruments must be shown to have construct validity. This is the degree to which the 
instrument measures the intended construct and can be assessed in a number of ways. The 
most sophisticated method of testing an instrument’s construct validity is to compare scores 
on it with those on a proven measure of the same construct (convergent and divergent 
validity). Convergent and divergent validity are the extents to which related and unrelated 
variables are associated [16, 39]. 
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Discriminative validity is the ability of the measure to distinguish between groups of 
respondents that differ according to some factor. 
While the above-mentioned psychometric properties are essential for any instrument, perhaps 
one of the most crucial requirements for a measure required to show change in QoL over a 
particular time period is the responsiveness [16, 39]. 
 
2.3.4. General considerations for translation and adaptation of QoL instruments 
The demand for valid QoL instruments available in several languages is growing rapidly. 
However, a majority of QoL instruments are developed in English-speaking countries. Since 
the development and validation of a new questionnaire require much time and labour and 
substantial monetary investment, the cultural adaptation of an internationally widely used 
instrument into Hungarian is the most frequently employed technique. 
The translation and validation methodologies employed to adapt such measures must ensure 
that the adapted version is comparable with the original and other national versions. The focus 
is on cross-cultural and conceptual, rather than on semantic equivalence. The instrument 
should be equally acceptable and should perform practically in the same way. In order to 
achieve this, a standardized methodology should be applied to all language versions 
developed [40]. 
 
2.3.5. QoL assessment in depression 
Recognition of the importance of HRQoL assessment in the field of chronic mental illnesses 
such as depression has increased during the past decade. The development of depression-
specific instruments was largely motivated by the introduction of new classes of 
antidepressants. Two depression-specific QoL inventories were published, the Quality of Life 
in Depression Scale (QLDS) by McKenna and Hunt (1992), and the Smith Kline Beecham 
Quality of Life Scale (SBQOL) by Stocker et al. (1992) (Table 3). Both were primarily 
developed for measuring change in clinical trials of antidepressants and are self-rating 
instruments. 
The SBQOL is a 23-item instrument that measures the dimensions of mood, psychological 
well-being, physical well-being, locus of control, social relationships and work/employment 
[41, 42]. 
The QLDS is a 34-item measure. It was developed in parallel in the UK and The Netherlands 
employing the ‘needs-based model’ of QoL. Qualitative in-depth interviews are conducted 
with patients with depression to explore the impact of the symptoms on their ability to fulfil 
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their needs and to examine the effects of medication on the patients and their illness. The 
items encompass 6 dimensions: domestic activities, interpersonal relationships, social life, 
cognition, personal hygiene, leisure activities and relaxation. The responses are recorded in a 
dichotomous format (true/not true), and then summed to give a total score ranging from 0 to 
34 [43, 44]. 
 
Type of instrument Instrument Reference 
Generic SF-36 Health Survey (SF-36) [45-56] 
 Sickness Impact Profile (SIP) [57] 
 WHO Quality of Life Assessment Instrument: 
      WHOQOL-100 
      WHOQOL-BREF  
 
[58-61] 
[62-66] 
 EuroQol (EQ-5D) [67-72] 
Depression-specific Smith Kline Beecham Quality of Life Scale 
(SBQOL) 
[73-75] 
 Quality of Life in Depression Scale (QLDS) [67, 72, 75-83] 
  
Table 3. Instruments appropriate for measuring QoL in depression 
 
Studies designed to asses QoL in depression concluded consistently that depression has an 
impairing effect on the HRQoL [39, 62, 75, 83-88,]. Other psychiatric disorders, such as 
anxiety disorders or schizophrenia, are also known to decrease the QoL, but not to the same 
extent as major depression [75, 86, 89]. Impairment among depressive patients was observed 
for all dimensions of HRQoL. This suggests that depression is not only reflected in mood and 
other mental symptoms, but also impairs an individual’s functioning ability in a number of 
ways. Depression has a significant effect on perceived physical functioning and bodily pain, 
and even on general health perceptions. Consequently, such impairment appears as reduced 
vitality, feeling ill, and having a limited social functioning ability. 
Evidence has been reported that the severity of depression is strongly associated with all 
dimensions of QoL [3, 83]. Furthermore, the effect of depression on the QoL was found to be 
comparable with those of other chronic conditions, e.g. arthritis, diabetes and hypertension 
[58, 84, 90, 91]. 
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3. AIMS 
___________________________________________________________________________ 
 
 
3.1. Drug utilization 
The aim of the drug utilization study was to analyse the changes in the amount and structure 
of Hungarian antidepressant consumption at national and regional levels between 1993 and 
2006. The possible relationship between antidepressant sales and trends in suicide rates was 
also investigated. To explore the reasons for regional differences in antidepressant 
consumption and suicide rates, their possible determinants, such as the indicators of 
psychiatric service and socio-economic factors, were also tested. 
Comparative analysis of hospital antidepressant consumption was performed through data 
derived from the four university-affiliated Psychiatric Departments. Since these are the 
leading professional medical institutions in the certain counties, there was an intention to 
compare the pattern of their antidepressant use with the county data too. 
 
3.2. Polypharmacy among psychiatric patients 
In recent years, no published data have been available regarding the quantitative analysis of 
multiple drug consumption in Hungary. Accordingly, a further objective of my studies was to 
evaluate the frequency of polypharmacy among psychiatric patients. The effects of 
comorbidity and demographic characteristics on multiple drug use were also analysed. 
 
3.3. Quality of life in depression 
As no suitable disease-specific measure of QoL in depression was available for Hungary, the 
decision was made to adapt an extensively used depression-specific QoL instrument, to 
evaluate its psychometric properties, and to assess the QoL in Hungarian patients with 
depression, employing the adapted QoL instrument in the clinical setting. The relationship of 
psychiatrist-rated and self-rated depression severity with the subjective QoL was also 
investigated. 
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4. METHODS 
________________________________________________________________ 
 
 
4.1. Drug utilization study 
 
4.1.1. National and regional trends of antidepressant consumption 
Retrospective analysis of sales data from the wholesalers to pharmacies and hospitals was 
performed on a 14-year period (1993-2006), applying the ATC/DDD methodology and 
classification system developed by the WHO (version 2006) [92]. Antidepressant drugs 
feature in the N06A therapeutic subgroup. For each Hungarian region (county), yearly crude 
wholesale data were kindly provided by the IMS PharmMIS Consulting Company. 
Nationwide and regional consumption was expressed as the number of DDDs per 1000 
inhabitant-days. Additionally, the number of active ingredients accounting for 90% of the 
total national antidepressant use was calculated. The DU90% segment was also determined at 
the regional level. 
A linear regression model was set up to investigate the trends in antidepressant utilization. 
The max./min. ratio was calculated to assess the interregional variation in antidepressant 
consumption. 
 
4.1.2. Hospital antidepressant consumption 
A 5-year (1999-2003) retrospective study of hospital antidepressant consumption was carried 
out at four university-affiliated Psychiatric Departments (in Budapest, Pécs, Debrecen and 
Szeged). The crude data on drug utilization were obtained from the hospital electronic patient 
health and medication record systems for the four Psychiatric Departments. The consumption 
was expressed as DDD/100 bed-days. The qualitative differences between the studied 
departments were determined on the basis of the DU90% segments. 
The study had the limitation that data on hospital antidepressant consumption were not 
available for the year 1999 at the Psychiatric Department in Debrecen. 
 
4.1.3. Relationship between antidepressant consumption and suicide rate 
Data on suicide rates were retrieved from the national mortality statistics (Hungarian Central 
Statistical Office) and were expressed in number of suicides/100000 inhabitants/year [93]. 
After the testing of normality (one-sample Kolmogorov-Smirnov test), the association 
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between the regional antidepressant consumption and the suicide rate was measured with the 
Pearson correlation. 
Regional data on psychiatric service indicators (the number of outpatient departments, the 
number of attendances, the number of new patients taken into care per 10000 inhabitants, and 
the number of hospital admissions per year) and the number of alcohol-abuse disorders were 
used to explore reasons for regional differences in antidepressant consumption and suicide 
rates; these data were provided by the NIPN (National Institute of Psychiatry and Neurology). 
Socio-economic data (GDP per inhabitant and unemployment rate) were extracted from the 
yearbooks of the Hungarian National Statistical Office [93]. After the testing of normality 
(one-sample Kolmogorov-Smirnov test), the Pearson correlation was employed to evaluate 
the impact of the above-mentioned determinants on the antidepressant consumption and 
suicide rates. An α level of 0.05 was adopted for all statistical analyses. 
 
4.1.4. Polypharmacy among psychiatric patients 
A cohort study was performed for a 1-year period. All inpatients (n = 983) admitted to the 
Psychiatric Department at the University of Szeged in 2001 were enrolled in the study. The 
patient characteristics (age, gender and diagnoses according to ICD-10) and all prescribed 
drugs (with their dose regimen) at discharge were collected from the electronic patient health 
and medication record system used at the Department. 
The generally accepted definition of polypharmacy is the chronic and concurrent use of 5 or 
more drugs [8, 94-96]. Accordingly, the patients were divided into two groups: the PP group: 
patients on 5 or more drugs; and the non-PP group: patients on less than 5 drugs. 
Student’s t-test was used to compare continuous or discrete data (the mean age, the mean 
numbers of used psychiatric drugs, other drugs and total drugs used). Linear regression was 
performed to examine the correlation between the increasing number of drugs used and the 
mean number of psychiatric drugs. Logistic regression was used to investigate the importance 
of factors predisposing to polypharmacy. p-values less than 0.05 (p < 0.05) were accepted as 
statistically significant. 
 
4.2. Measuring quality of life in depression 
 
4.2.1. Selection criteria of the QoL instrument employed 
 It should be easy for the patients to complete (average time for completion the 
questionnaire should be less than 10 min) [16, 97]. 
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 The items should be generated directly from patients with depression as its content 
should be relevant to this population, and expressed in the actual words of the 
depressed patients [39]. 
 It should be easy for the physician or researcher to administer. 
 There should be strong evidence of its validity, good reliability and internal 
consistency. 
 There should be responsiveness to changes in health status and QoL [16]. 
The QLDS is a widely used depression-specific instrument that satisfies the above-mentioned 
requirements of a good QoL measure. The questionnaire has been adapted and re-validated 
for use in almost 20 countries worldwide in the last few years. [98]. 
 
4.2.2. Hungarian adaptation of the QLDS 
 
4.2.2.1. Patients and study design (procedures) 
The Hungarian adaptation of the QLDS consisted in three stages: 
1. Translation of the questionnaire into Hungarian from the original English 
2. Field-testing of the translated QLDS for face and content validity 
3. Assessment of the psychometric properties of the Hungarian QLDS 
 
Translation 
In the translation process, the dual panel approach was employed. This methodology involves 
two separate translation panels (bilingual and lay) and focuses on the conceptual equivalence 
of the target questionnaire to the original, rather than attempting to achieve linguistic or 
semantic equivalence. 
The aim of the bilingual panel was to produce an initial translation for each of the measure’s 
34 items. The panel consisted of 5 Hungarians fluent in the English language. Emphasis was 
placed on achieving conceptual equivalence and cultural relevance of the translated items. 
The lay panel (composed of 7 monolingual Hungarians without academic education) 
considered the translation provided by the bilingual panel to ensure that the wording of the 
items would be appropriate for an average patient. 
 
Field-testing of the translated QLDS for face and content validity 
The aim of the field-test interviews was to assess the face and content validity of the 
translated QLDS. Field-test interviews were conducted by myself with 25 inpatients with 
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depression at the Department of Psychiatry (affiliated to the University of Szeged Faculty of 
Medicine). The patients were diagnosed as depressed according to the diagnostic criteria of 
ICD-10 by a psychiatrist. In the course of the field-test interview, the patients were asked to 
provide demographic information and then to complete the QLDS. The patients were 
observed while they completed the questionnaire and were then asked a number of questions 
concerning the suitability and acceptability of the QLDS. 
 
Assessment of the psychometric properties of the Hungarian QLDS 
The psychometric properties of the Hungarian measure were tested by means of a postal 
survey with 50 out-patients with depression. Patient recruitment was arranged during regular 
psychiatric appointments at the Department of Psychiatry (affiliated to the University of 
Szeged, and Semmelweis University, Budapest). The ICD-10 diagnosis was established by 
the psychiatrist at the same visit. The patients who agreed to take part in the study were given 
a package consisting of the Hungarian QLDS, a demographic questionnaire, the Shortened 
Beck Depression Inventory (BDI) and the Nottingham Health Profile (NHP). The participants 
completed the questionnaires at home (Time 1) and sent them back to the researcher. Two 
weeks after receipt of the completed questionnaires, the participants were sent a similar 
package by post (Time 2). 
In order to achieve a homogeneous sample, patients were excluded from the study if they had 
a diagnoses other than F30-F39 and F4120 (mixed anxiety and depressive disorder) according 
to the ICD-10 diagnostic criteria system. 
The study was approved by the appropriate institutional ethical committee and all patients 
provided their written consent prior to study entry. 
 
4.2.2.2. Instrument used 
The QLDS consists of 34 items with dichotomous responses (’yes/no’) scored 0 or 1. The 
total score on the scale can therefore range from 0 to 34, with a higher score indicating a 
lower QoL [43, 44]. 
The demographic questionnaire collected sociodemographic information about the patients 
and asked the respondents to rate their general health and the severity of their depression. 
The Nottingham Health Profile (NHP) is a generic measure containing 38 items in 6 sections 
(physical mobility, pain, emotional reactions, energy level, social isolations and sleep). The 
scores in each of the sections can vary from 0 to 100, with a higher score indicating greater 
distress in that section. An index of distress (the NHPD) can be calculated from the responses 
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to the NHP. This scale, which consists of 24 items, can vary from 0 to 24, with a higher score 
indicating greater distress [30, 31, 40]. 
The severity of depression was determined with the 9-item Shortened Beck Depression 
Inventory (BDI). Individual item scores range from 0 to 3 and the total scores from 0 (no 
depression) to 60 (severe depression) [99-101]. 
 
4.2.2.3. Statistical analysis 
Reliability (determined by establishing the test-retest reliability of the measure) was expressed 
as a two-tailed Spearman’s coefficient. The test-retest reliability of a measure is an estimate of 
its reproducibility over time when no change in condition has taken place. It is assessed by 
correlating scores on the QLDS collected through two separate administrations. A high 
correlation indicates that the instrument produces low random measurement error, with a 
minimum value of 0.85 required [16, 39]. 
The internal consistency of the instrument was calculated by using the Cronbach’s α. A value 
above 0.70 indicates that the items in the scale are adequately related [16, 39]. 
Evidence of construct validity for the Hungarian QLDS was provided by estimating the 
convergent and divergent validity, assessed by relating the scores on the QLDS to those on 
the NHP. It was predicted that the QLDS scores would be more closely related to the NHP 
scores in the emotional reactions and social isolation sections than to those in the pain and 
physical mobility sections. The two-tailed Spearman’s coefficient was used to assess the level 
of this association.  
The discriminative validity of the QLDS was assessed by determining the scale’s ability to 
distinguish between groups of respondents differing according to the perceived health status, 
the perceived severity of depression (demographic questionnaire) and the severity of 
depression measured by the BDI. Kruskal-Wallis tests were employed to compare different 
subgroups. The ability of the QLDS to discriminate between participants on the basis of their 
ICD severity diagnosis (clinically depressed or in remission) was tested by using the Mann-
Whitney U test. 
p values < 0.05 were considered statistically significant. Statistical analyses were performed 
with the 13.0 version of SPSS program package. 
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4.2.3. Clinical performance of the Hungarian QLDS in measuring QoL for patients with 
depression  
 
4.2.3.1. Patients and study design 
The subjects were 48 outpatients recruited by psychiatrists during regular psychiatric 
appointments at three psychiatric departments (in Szeged, Pécs and Budapest). All these 
patients were diagnosed with a depressive disorder by the psychiatrist according to the ICD-
10 diagnostic criteria system. The patients were requested to complete a questionnaire 
package consisting of the Hungarian QLDS, a demographic questionnaire, the shortened BDI 
and the NHP. The severity of depression was established on two psychiatrist-administered 
scales: the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Asberg 
Depression Rating Scale (MADRS). Questionnaires were completed and the scores for each 
scale were collected after a 4-5-week follow-up period, during the next psychiatric 
appointment.  
Written informed consent was obtained from all subjects, and the study was approved by the 
institutional ethical committee at all sites. 
 
4.2.3.2. Statistical analysis 
Comparative analysis of the obtained QLDS scores regarding gender and subtypes of 
depression was performed with the Mann-Whitney U test. 
The differences in QoL between groups of respondents who differed in severity of depression 
as measured by the HAM-D were assessed with the Kruskal-Wallis test. 
The two-tailed Spearman’s coefficient was used to assess the correlation between the 
psychiatrist’s rating of the severity of depression (HAM-D and MADRS) and the patient’s 
perception of the HRQoL (QLDS and NHP) and of the severity of depression (BDI). Because 
of the multiplicity, a more conservative α-value of 0.01 was used to test significance. 
The hypothesis that a clinical improvement in depression rating would result in an 
improvement in QoL was tested with the two-tailed Spearman correlation between the 
changes in the HAM-D and MADRS score and the QLDS score. 
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5. RESULTS 
___________________________________________________________________________ 
 
 
5.1. Drug utilization study 
 
5.1.1. National trend of antidepressant consumption 
The nationwide use of antidepressants progressively increased in Hungary during the studied 
period, from 4.03 in 1993 to 25.71 DDD/1000 inhabitants/day in 2006. It means a more than 
6-fold increase as compared to the base year (Figure 1). 
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Figure 1. Structure of antidepressant consumption in Hungary 
 
An extensive increase in the number of registered products was observed during the studied 
14-year period. Whereas 23 antidepressant preparations were on the Hungarian market at the 
beginning of the study, at the end this number had risen to 133. This was not merely a result 
of the broader selection of active ingredients (11 new substances were introduced), but rather 
reflected the availability of generic drugs. 
After the marketing authorization of SSRIs, not only the volume of antidepressant 
consumption, but also the structure altered considerably. The changes in the utilization of 
active ingredients are demonstrated by the trend analysis in Table 4. 
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The sales of the TCAs decreased slightly during the studied period (from 3.17 DDD/1000 
inhabitants/day to 1.00 DDD/1000 inhabitants/day). The results of the trend analysis indicated 
that the usage of clomipramine underwent a moderate increase, and was responsible for the 
highest consumption in this group. However, the use of amitriptyline declined, from 0.85 in 
1993 to 0.07 DDD/1000 inhabitants/day in 2000, it had a 3-fold elevation to 0.21 DDD/1000 
inhabitants/day in the last 6 years. Imipramine, dibenzepine and maprotiline exhibited 
continuously decreasing consumption. Nevertheless, maprotiline remained the second most 
prominent active ingredient in this group (Figure 2; see page 20) 
 
 First 
year* 
2006 Diff. Diff.% R p 
N06A Antidepressants 4.03 25.71 21.68 418 0.991 <0.05 
N06AA Non-selective monoamine 
reuptake inhibitors 
3.17 1.01 2.16 -68 -0.967 <0.05 
  N06AA02 imipramine 0.35 0.06 0.29 -82 -0.911 <0.05 
  N06AA04 clomipramine 0.06 0.44 0.38 633 0.604 <0.05 
  N06AA06 trimipramine 0.15 0.02 0.13 -86 -0.902 <0.05 
  N06AA08 dibenzepin 0.46 0.05 0.41 -89 -0.948 <0.05 
  N06AA09 amitriptyline 0.85 0.21 0.64 -75 -0.878 <0.05 
  N06AA21 maprotiline 1.37 0.21 1.16 -85 -0.958 <0.05 
N06AB Selective serotonin reuptake 
inhibitors 
0.69 18.24 17.55 2543 0.992 <0.05 
  N06AB03 fluoxetine 0.18 1.23 1.05 583 0.533 <0.05 
  N06AB04 citalopram 0.60 5.75 5.15 858 0.958 <0.05 
  N06AB05 paroxetine 0.06 5.12 5.06 8433 0.977 <0.05 
  N06AB06 sertraline 0.04 4.70 4.66 11650 0.984 <0.05 
  N06AB08 fluvoxamine 0.67 0.60 0.07 10 0.231 0.427 
  N06AB10 escitalopram 0.015 0.83 0.815 5433 0.871 0.129 
N06AG MAO-A inhibitors 0.17 1.10 0.93 547 0.869 0.143 
  N06AG02 moclobemide 0.17 1.10 0.93 547 0.869 0.143 
N06AX Other antidepressants 0.05 5.35 5.3 10600 0.943 <0.05 
  N06AX03 mianserin 0.05 0.59 0.54 1080 0.870 <0.05 
  N06AX05 trazodone 0.01 0.01 0 0 0.283 0.327 
  N06AX11 mirtazapine 0.10 1.62 1.52 1520 0.855 <0.05 
  N06AX14 tianeptine 0.18 0.89 0.71 394 0.903 <0.05 
  N06AX16 venlafaxine 0.001 1.51 1.50 150000 0.864 <0.05 
  N06AX18 reboxetine 0.004 0.09 0.086 2150 0.731 <0.05 
* first year when consumption was indicated according to the data of the wholesalers   
 
Table 4. Trend analysis of antidepressant consumption in Hungary in the period 1993-2006 
 
A marked elevation was observed in the consumption of SSRIs (from 0.69 to 18.24 
DDD/1000 inhabitants/day). The share of this group in the total consumption of 
antidepressants gradually increased from 17% to 71% by 2006 (Figure 3; see page 21). The 
usage of sertraline and paroxetine displayed the most marked increases among the SSRIs. 
Citalopram was the most frequently used active ingredient in this group at the end of the 
studied period. Fluvoxamine was the most rarely used SSRI; its consumption remained 
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relatively unchanged throughout the studied 14-year period. The utilization of fluoxetine rose 
9-fold from 0.18 to 1.62 DDD/1000 inhabitants/day in the 5 five years, but then remained 
relatively constant. Since the marketing authorization of escitalopram occurred at the end of 
2002, a measurable consumption was indicated only during the last 2 years of the studied 
period. 
From the MAO-A inhibitors group, merely moclobemide is registered in Hungary, and its 
consumption demonstrated a slow, moderate increase (from 0.17 to 1.10 DDD/1000 
inhabitants/day). It accounted for only the 4% of the total antidepressant consumption. 
A considerable utilization of the “other antidepressants” (N06AX group) was detected for 
1996, due to mianserin (0.35 DDD/1000 inhabitants/day in 1997) at that time. The 
consumption of this group rose to 5.35 DDD/1000 inhabitants/day in 2006 (i.e. 20% of the 
total consumption). Mirtazapine, venlafaxine and tianeptine were the most widely used agents 
in this group (Figure 4; see page 22). 
The DU90% segment underwent an enlargement during the last 14 years. While only 6 active 
ingredients accounted for 90% of the use in 1993, this number had risen to 10 in 2006 (Figure 
5). 
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Figure 5. Antidepressant consumption in 2006, DU90% segment 
 
DU90% 
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Figure 2. Consumption of non-selective monoamine reuptake inhibitors (N06AA): percental 
rate of total consumption, and structure 
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Figure 3. Consumption of selective serotonin reuptake inhibitors (N06AB): percental rate of 
total consumption, and structure 
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Figure 4. Consumption of” other antidepressants” (N06AX): percental rate of total 
consumption, and structure 
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5.1.2. Regional differences in antidepressant consumption 
The antidepressant consumption in the 19 counties and the capital (Budapest) exhibited a 
marked elevation during the studied period, similarly to the national trend. However, 
significant quantitative differences were observed between certain counties. For each year in 
the period 1993-2006, there was a 1.6-2.6 (min.-max.)-fold difference between the regions 
with the lowest and the highest antidepressant consumption (Table 5). 
The ranking of the individual regions according to their total antidepressant consumption was 
basically the same throughout the 14-year study period (Spearman, 0.533 < r < 0.988; p < 
0.05 for all years tested); hence certain regions were permanently high consumers, whereas 
others remained permanently low consumers. Budapest, Békés, Bács-Kiskun and Csongrád 
counties generally proved to be the most prominent antidepressant consumers. However, 
Gyır-Moson-Sopron took over the leading position with the highest antidepressant usage in 
2005 and 2006. Zala, Szabolcs-Szatmár-Bereg, Jász-Nagykun-Szolnok and Borsod-Abaúj-
Zemplén counties were the lowest consumers during the studied period. 
 
Antidepressant utilization Suicide rate 
(DDD/1000 inhabitants/day) (suicide/100000 inhabitants) 
County 1993 2006 Diff. Diff.% 1993 2006 Diff. Diff.% 
Bács-Kiskun 4.7 29.1 24.4 519 50.4 34.3 -16.1 -31.9 
Baranya 3.2 28.9 25.7 803 32.4 23.9 -8.5 -26.2 
Békés 4.0 29.9 25.9 647 47.9 34.6 -13.3 -27.7 
Borsod-Abaúj-Zemplén 3.1 19.0 15.9 513 36.4 25.5 -10.9 -29.9 
Budapest 5.3 26.8 21.5 405 28.1 18.4 -9.7 -34.5 
Csongrád 4.9 29.9 25.0 510 50.1 35.6 -14.5 -28.9 
Fejér 2.0 22.1 20.1 1005 32.4 23.3 -9.1 -28.0 
Gyır-Moson-Sopron 3.5 30.8 27.3 780 19.0 19.5 0.5 2.6 
Hajdú-Bihar 4.3 24.0 19.7 458 46.8 36.2 -10.6 -22.6 
Heves 4.8 28.8 24.0 500 31.9 20.3 -11.6 -36.4 
Jász-Nagykun-Szolnok 4.0 19.4 15.4 385 45.2 31.8 -13.4 -29.6 
Komárom-Esztergom 2.3 22.5 20.2 878 36.8 19.4 -17.4 -47.3 
Nógrád 4.1 21.5 17.4 424 28.8 23.4 -5.4 -18.7 
Pest 3.7 25.6 21.9 592 36.1 20.1 -16.0 -44.3 
Somogy 2.9 22.1 19.2 662 33.3 25.2 -8.1 -24.3 
Szabolcs-Szatmár-Bereg 2.3 21.9 19.6 852 47.0 24.1 -22.9 -48.7 
Tolna 3.4 20.8 17.4 512 45.5 21.9 -23.6 -51.8 
Vas 4.4 24.4 20.0 454 19.4 16.3 -3.1 -15.9 
Veszprém 2.8 21.6 18.8 671 23.8 20.9 -2.9 -12.2 
Zala 2.4 18.0 15.6 650 30.5 19.4 -11.1 -36.4 
Total (national level) 4.0 25.7 21.7 542 35.7 24.4 -11.3 -31.6 
  
Table 5. Regional differences in antidepressant consumption and suicide rate 
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The most pronounced elevation in antidepressant consumption occurred in Fejér country 
(1005%, from 2.0 in 1993 to 22.1 DDD/1000 inhabitants/day in 2006), whereas Jász-
Nagykun-Szolnok county showed the lowest elevation, 385% (from 4.0 in 1993 to 19.4 
DDD/1000 inhabitants/day in 2006). 
Basically, the structure of antidepressant consumption in the counties was similar to the 
national pattern. The increasing use of SSRIs and “other antidepressants” the usage of TCAs 
pushed into the background. 
Both at the start and at the end-point of the study, all the antidepressant classes displayed a 
large interregional variation in their use (max./min. ratio > 2) (Table 6). 
The relative use of the different antidepressant groups did not differ between the regions. The 
number of active ingredients in the DU90% ranged from 8 to 10 at the end of the studied 
period. The pattern of the regional DU90% segment was similar to that observed for the total 
national consumption (Figure 5). 
 
  1993 2006 
  DDD/1000 inhabitants/day DDD/1000 inhabitants/day 
  Mean ± SD Min. Max. Ratio 
max./min. 
Mean ± SD Min. Max. Ratio 
max./min. 
N06A Antidepressants 3.65 ± 1.01 2.01 5.3 2.64 24.32 ± 4.02 18.02 30.82 1.71 
N06AA Non-selective 
monoamine 
reuptake 
inhibitors 
2.92 ± 0.89 1.50 4.16 2.79 0.92 ± 0.24 0.58 1.58 2.73 
N06AB Selective 
serotonin 
reuptake 
inhibitors 
0.57 ± 0.21 0.28 1.09 3.91 17.09 ± 2.70 12.48 21.43 1.72 
N06AG MAO-A 
inhibitors 
0.15 ± 0.06 0.03 0.25 8.33 1.13 ± 0.46 0.60 2.12 3.54 
N06AX Other 
antidepressants 
n.c.* 5.17 ± 1.20 3.56 7.44 2.09 
* not calculable (not detectable consumption) 
Table 6. Mean, minimum and maximum regional antidepressant consumption in 1993 and 
2006 
 
The only determinant among the psychiatric service indicators which showed a significant 
association with the antidepressant consumption at the regional level was the number of 
attendances in outpatient departments (Table 7). No correlation was found with the number of 
outpatient departments, the number of new patients taken into care per 10000 inhabitants, or 
the number of hospital admissions. Moreover, the number of alcohol-abuse disorders did not 
indicate a significant correlation with the antidepressant consumption. There was a trend 
towards a positive association with the GDP per inhabitant, but this did not reach statistical 
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significance in any year. The regional unemployment rates likewise did not indicate a 
significant association with the antidepressant use. 
 
 Antidepressant 
consumption 
Suicide rate 
 (rmin; rmax) (rmin; rmax) 
Economic factors:   
   Unemployment rate -0.140; -0.441 0.014; 0.484 
   GDP/inhabitant 0.232; 0.547 -0.301; -0.443 
Psychiatric service indicators:   
   Number of outpatient departments 0.268; 0.440 -0.093; -0.293 
   Number of attendances 0.445; 0.584 -0.009; -0.231 
   New patients taken into care per  
   10000 inhabitants 
0.078; 0.132 0.055; 0.268 
   Number of patients sent to hospital 0.056; 0.335 -0.111; -0.309 
Alcohol abuse and addiction 0.017; 0.293 0.054; 0.271 
  
Table 7. Associations between antidepressant consumption or suicide rate and various 
determinants  
 
5.1.3. Relationship between antidepressant consumption and suicide rate 
The national suicide rate has undergone a steady, moderate decline, from 35.7 
suicides/100000 inhabitants/year in 1993 to 24.4 suicides/100000 inhabitants/year in 2006 
(Figure 6). 
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Figure 6. Antidepressant consumption and suicide rate in Hungary, 1993-2006 
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Significant differences were found between regions as regards the suicide rate (Table 5). For 
each year in the period 1993-2006, there was a 2.2-3.8 (min.-max.)-fold difference between 
the regions with the lowest and the highest suicide rate. An increasing suicide rate was 
experienced only in the case of Gyır-Moson-Sopron county. The analysis of the regional 
differences in suicide rates demonstrated heterogeneity between the western and southern 
regions (Figure 7). The suicide rate was found to be about 3 times higher in the central and 
southern part of Hungary than in the west. The correlation between antidepressant 
consumption and suicide rate did not prove to be statistically significant in terms of the 
regional data (rmin = -0.053; rmax = -0.314). There was a trend towards a negative relationship 
between the psychiatric service indicators and the suicide rate, but this did not reach the level 
of statistical significance (Table 7). Moreover, the GDP per inhabitant was negatively 
associated with the regional suicide rate. No significant correlation was found for the other 
tested determinants at a regional level, e.g. the unemployment rate, or alcohol-abuse 
disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Regional suicide rates and antidepressant consumption in 1993 and 2006 
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5.1.4. Hospital antidepressant consumption 
The hospital antidepressant consumption displayed a significant elevation at each of the four 
university-affiliated psychiatric departments during the studied 5-year period (1999-2003). 
However, considerable quantitative differences were noted between certain departments 
(Figure 8). 
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Figure 8. Antidepressant consumption at the four university-affiliated Psychiatric 
Departments 
 
The following significant differences were found in relation to the structure of antidepressant 
consumption between the four psychiatric departments: 
 The numbers of active ingredients in the DU90% segment were significantly different 
in Szeged and Budapest (Table 8). 
 The Psychiatric Department in Budapest reported the most considerable use of TCAs 
(mean: 9.1 ± 2.1 DDD/100 bed-days). 
 While clomipramine was the most prominent TCA at the Psychiatric Department in 
Budapest, Debrecen and Szeged, dibenzepine and maprotiline were preferred in Pécs. 
 As concerns the use of SSRIs, the trends moved in parallel at the four Departments 
with the exception of escitalopram. Exclusively, the Psychiatric Department in Pécs 
indicated a detectable escitalopram consumption. 
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 Budapest proved to be the lowest consumer of “other antidepressants”, which reached 
only 5.1 DDD/100 bed-days in 2003, whereas the use of this group rose to 29.7 in 
Pécs, to 38.8 in Szeged, and to 28.9 DDD/100 bed-days in Debrecen. 
 
Szeged Debrecen Pécs Budapest 
Venlafaxine Citalopram Paroxetine Citalopram 
Citalopram Paroxetine Venlafaxine Paroxetine 
Mirtazapin Tianeptine Mirazapine Clomipramine 
Sertraline Mianserin Sertraline Mianserin 
Paroxetine Sertraline Escitalopram  
Fluoxetine Venlafaxine Citalopram  
Moclobemide    
  
Table 8. DU90% segments at the four Psychiatric Departments, 2003 
 
5.2. Polypharmacy among psychiatric patients 
In the studied group (n = 984) 33.6% of the patients (331) were found to be on 5 or more 
drugs. 
The mean age of the PP group was 61 (±15.94) years, which was significantly (p < 0.001) 
higher than the 41 (±15.21) years mean age of the non-PP group (Table 9). 
 
 PP group 
n = 331 
Non–PP group 
n = 653 
n (%) 33.6 66.4 
Female (%) 75 64 
Male (%) 25 36 
Mean age (±SD) 60.8 (±15.94)* 41.5 (±15.21) 
Mean number of drugs used (±SD): 
   total 
   psychiatric 
   other 
 
7.3 (±2.35) 
3.2 (±1.11)* 
4.1 (±2.54) 
 
2.8 (±0.93) 
2.4 (±0.85) 
0.4 (±0.67) 
* Statistically significant PP group vs Non-PP group; p < 0.001, t-test  
Table 9. Patient characteristics and mean number of drugs used 
 
Both groups were characterized by a female dominance. The mean age of the females was 52 
(±16.68) years, which was significantly (p < 0.001) higher than the 47 (±18.05) years mean 
age of males among all the patients involved in the study. 
In the overall group involved in the study, 70% of the patients were prescribed 2 or 3 
psychopharmacons simultaneously. 
In the PP group, the mean number of drugs used concurrently and chronically was 7.3 (±2.35; 
max = 16), of which the mean number of drugs with psychiatric indications was 3.2 (±1.11) 
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(Table 9). In the non-PP group, the mean number of drugs used concurrently and chronically 
was 2.8 (±0.93), of which the mean number of drugs with psychiatric indications was 2.4 
(±0.85).  
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Figure 9. Distribution of patients as concerns the number of psychiatric drugs used in the PP 
group and the non-PP group 
 
Figure 9 depicts the distribution of the patients concerning the number of psychiatric drugs 
used simultaneously. 
The mean number of drugs with psychiatric indications among the patients in the PP group 
was significantly (p < 0.001) higher than that among the patients in the non-PP group. The 
number of psychiatric drugs in the PP group did not increase as the number of concurrently 
used drugs increased, the average number remaining at about 3. The linear regression analysis 
revealed that the mean number of psychiatric drugs was not significantly associated with the 
increasing number of drugs used (r = 0.45; p = 0.15; b = 0.07; a = 2.71) (Figure 10). 
The prevalence of monotherapy in psychiatric treatment was 5.1% in the PP group and 14.5% 
in the non-PP group. 
The mean value of “other medication” (those with a non-psychiatric indication) was 4.1 
(±2.54; max. = 13) in the PP group, and 0.4 (±0.67; max. = 3) in the non-PP group. 
The number of drugs used (both psychiatric and “other” medications) in the two genders did 
not indicate a significant difference in either group. 
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Figure 10. The average number of psychiatric drugs used by polypharmacy patients 
 
Logistic regression demonstrated a significant correlation between the polypharmacy and the 
assessed factors (comorbitity, age and gender). The value of the constant of the logistic 
regression equation was a = -4.8803. According to this analysis, comorbidity is the most 
important predisposing factor for PP among the investigated factors (OR = 3.5670). The value 
of odds ratio (OR) for gender proved to be 1.4480. Exp bage (1.0571) is the increase in the OR 
of becoming polypharmacy for every increase of 1 year age (Table 10). 
 
Variable bi S.E. Expbi=OR 95% CI p 
Gender 0.3702 0.1768 1.4480 1.0240 2.0476 0.0362 
Age 0.0555 0.0053 1.0571 1.0462 1.0680 0.0000 
Comorbidity 1.2717 0.1581 3.5670 2.6164 4.8630 0.0000 
  
Table 10. Edited output from logistic regression analysis 
 
The most common psychiatric diagnoses are the different types of mood disorders (F30-F39 
according to the ICD-10 diagnostic criteria system) in both groups: PP group: 49%; non-PP 
group: 48% (Table 11). 92% of the patients with a diagnosis of depression were on 
monotherapy in terms of antidepressant use, and only 7.7% were prescribed 2 antidepressants 
simultaneously.  
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Diagnosis ICD-10 PP group 
(%) 
Non-PP group 
(%) 
Mood disorders F30-F39 49 48 
Organic, including symptomatic, mental 
disorders 
F00-F09 40 10 
Neurotic, stress-related and somatoform 
disorders 
F40-F48 27 33 
Schizophrenia, schizotypal and delusional 
disorders 
F20-F29 12 29 
Disorders of adult personality and behaviour F60-F69 4.3 14 
  
Table 11. The most common psychiatric diagnoses 
 
Piracetam leads the toplist of psychiatric drugs in the PP group. Antidepressants (citalopram 
and carbamazepine) and anxiolytics (alprazolam and clonazepam) are the most frequently 
used psychiatric drugs in both groups (Table 12). Carbamazepine is utilized as a mood 
stabilizer in psychiatry. Drugs with a cardiovascular indication lead the toplist of “other” 
medication (in both groups), which is justified by the fact that cardiovascular diseases are the 
most common diagnoses among the comorbidity. 68% of the patients suffered from 
cardiovascular disease. 
 
Polypharm group 
Psychiatric drugs Other drugs 
ATC  % of users ATC  % of users 
N06BX03 Piacetam 36 C07AB02 Metoprolol 34 
N05BA12 Alprazolam 33 C07AA02 Enalapril 26 
N03AB01 Clonazepam 32 B01AA02 Acetylsalicylic acid 24 
N06AB04 Citalopram 22 A02BA03 Famotidine 21 
N03AF01 Carbamazepine 16 C04AD03 Pentoxyphylline 10 
 
Non-polypharm group 
Psychiatric drugs Other drugs 
ATC  % of users ATC  % of users 
N03AB01 Clonazepam 34 C07AB02 Metoprolol 4 
N05BA12 Alprazolam 27 C07AA02 Enalapril 3 
N03AF01 Carbamazepine 14 A02BA03 Famotidin 2,2 
N06AB04 Citalopram 12 H03AA01 L-thyroxine 1,9 
N05AH03 Olanzapine 11 A06AB06 Sennosides 1,8 
  
Table 12. List of most frequently used drugs 
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5.3. Hungarian adaptation of the QLDS 
 
5.3.1. Translation 
No major difficulties were experienced in producing conceptually equivalent items. The 
bilingual panel was unable to make a decision on 6 items and 2 alternative translations of each 
were sent for consideration by the lay panel. The lay panel had no problem with the 
translations provided and was able to select the most appropriate of the alternative versions 
presented to them. 
 
5.3.2. Field-test interviews 
The QLDS was completed satisfactory by the field-test sample (n = 25) with no missing 
responses. The mean time required to complete the QLDS was 9.2 (±3.9) min. The 
sociodemographic characteristics of the field-test sample and the distribution of the patients 
according to the depression subtypes are shown in Table 13. 
 
Field-test sample  
(n=25) 
Postal survey sample  
(n=50) 
Gender 
  Male 
  Female 
n (%) 
7 (28) 
18 (72) 
n (%) 
13 (26) 
37 (74) 
Age (years) 
  Range 
  Mean (SD) 
 
22-68 
46.9 (12.0) 
 
23-80 
48.7 (13.2) 
Marital status 
  Married 
  Divorced 
  Single 
  Widowed 
n (%) 
16 (64) 
8 (32) 
- 
1 (4) 
n (%) 
30 (60) 
7 (14) 
9 (18) 
4 (8) 
Employment status 
  Employed (full/part-time) 
  Disability pensioner 
  Retired 
  Long-term sick 
  Homemaker 
  Unemployed 
  Student 
n (%) 
6 (24) 
14 (56) 
2 (8) 
2 (8) 
1 (4) 
- 
- 
n (%) 
12 (24) 
19 (38) 
3 (6) 
7 (14) 
3 (6) 
5 (10) 
1 (2) 
Duration of illness (years) 
  Range 
  Mean (SD) 
  Median 
 
1-30 
10.7 (7.8) 
10.0 
0.5-38 
10.2 (8.9) 
8.0 
Subtypes of depression 
  Organic mood disorder 
  Bipolar affective disorder 
  Unipolar affective disorder 
  Persistent mood disorder 
  Mixed anxiety and  
  depressive disorder 
n (%) 
1 (4) 
2 (8) 
15 (60) 
2 (8) 
5 (20) 
n (%) 
1 (2) 
5 (10) 
33 (66) 
1 (2) 
10 (20) 
  
Table 13. Details of the field-test and postal survey samples 
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5.3.3. Assessment of psychometric properties (postal survey) 
Details of the postal survey participants (n = 50) are shown in Table 13. The scores obtained 
on the QLDS, NHP and BDI are presented in Table 14. 
No significant differences in QLDS scores were detected between participants who were 
above and below the median sample age (51 years) or between males and females (Mann-
Whitney U test: p > 0.05 at each time point). 
 
Time 1 Time 2  
Mean  
(SD) 
Range 
Median 
 (IQR) 
Mean 
(SD) 
Range 
Median 
 (IQR) 
QLDS 14.4 (5.6) 20.0 
13.0 
(10.0-19.2) 
14.4 (5.8) 19.0 
13.0 
(10.0-20.0) 
BDI 11.5 (5.8) 49.0 
28.0 
(13.0-38.0) 
11.6 (6.1) 51.0 
27.0 
(15.25-36.5) 
NHPD 10.5 (5.6) 22.0 
10.0 
(5.75-15.2) 
10.6 (5.6) 22.0 
11.0 
(5.0-15.0) 
  energy level 65.3 (35.6) 100.0 
66.6 
(33.3-100.0) 
68.0 (36.8) 100.0 
66.6 
(33.3-100.0) 
  pain 21.2 (26.6) 75.0 
12.5 
(0.0-37.5) 
20.2 (26.5) 87.5 
6.25 
(0.0-37.5) 
  emotional  
  reactions 
50.9 (29.8) 100.0 
44.4 
(22.2-77.7) 
51.5 (29.4) 100.0 
55.5 
(30.5-77.7) 
  sleep 43.6 (32.2) 100.0 
40.0 
(15.0-60.0) 
43.6 (30.4) 100.0 
40.0 
(20.0-60.0) 
  social isolation 46.4 (31.1) 100.0 
40.0 
(20.0-65.0) 
46.0 (33.9) 100.0 
40.0 
(20.0-80.0) 
  physical  
 mobility 
28.2 (24.3) 75.0 
25.0 
(12.5-50.0) 
29.5 (23.2) 87.5 
31.25 
(12.5-50.0) 
QLDS, Quality of Life in Depression Scale; BDI, Beck Depression Inventory; NHPD, 
Nottingham Health Profile distress index  
 
Table 14. Descriptive statistics for main outcome measures (postal survey, n = 50) 
 
Test-retest reliability and internal consistency 
The test-retest reliability coefficient was 0.89, indicating that the measure had good 
reproducibility and produced a low level of random measurement error. The internal 
consistency (as measured by the Cronbach’s α coefficient) was 0.945 at Time 1 and 0.951 at 
Time 2, showing an adequate interrelatedness of the items. 
Construct validity 
The QLDS indicated appropriate levels of convergent and divergent validity at both 
applications (Table 15). 
The QLDS demonstrated the expected strong correlations with the scores on the emotional 
reactions (Time 1: r = 0.75; Time2: r = 0.76) and social isolation (Time 1: r = 0.68; Time 2: r 
= 0.79) sections of the NHP. As anticipated, lower correlations were found between the 
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QLDS and the pain (Time 1: r = 0.39; Time 2: r = 0.22) and physical mobility (Time 1: r = 
0.39; Time 2: r = 0.49) sections of the NHP. 
A high correlation was found with the BDI score at each time point (Time 1: r = 0.83; Time 2: 
r = 0.83). 
 QLDS Time 1 
(Spearman coefficient) 
QLDS Time 2 
(Spearman coefficient) 
NHP section   
Energy level 0.54 0.43 
Pain 0.39 0.22 
Emotional reactions 0.75 0.76 
Sleep 0.47 0.24 
Social isolation 0.68 0.79 
Physical mobility 0.39 0.50 
BDI score 0.83 0.83 
NHP, Nottingham Health Profile; BDI, Beck Depression Inventory  
Table 15. Correlation between QLDS and NHP section scores and BDI score in the postal 
survey (Spearman coefficient) 
 
Discriminative validity 
The participants who perceived their depression to be worse had significantly higher QLDS 
scores, as did the patients who rated their general health to be poorer (Table 16). 
The participants who were currently classified as clinically depressed according to their ICD-
10 diagnosis had significantly higher QLDS scores than the patients who were in remission on 
the basis of the Mann-Whitney U test (ptime1 = 0.018; ptime2 = 0.012). 
Additional evidence for the discriminative validity of the Hungarian QLDS was gained from 
the differences in QLDS scores related to the severity of depression as assessed by the BDI. 
On the basis of the BDI score, the participants who were considered ‘mildly depressed gave 
significantly lower QLDS scores (Time 1: 10.11±3.10; Time 2: 10.4±2.45) than those 
considered ‘severely depressed’ (Time 1: 17.88±5.36; Time 2: 17.51±5,546). Results of 
Kruskal-Wallis test: ptime1, ptime2 < 0.05. 
 
 Time 1 Time 2 
 n Median (IQR) p* n Median (IQR) p* 
Perceived severity of 
depression 
      
   mild 10 10.5 (8.5-12.3)  7 10.0 (8.0-14.0)  
   moderate 33 13.0 (10.0-19.0) 0.002 33 12.0 (10.0-16.5) 0.001 
   severe 7 21.0 (17.0-24.0)  10 21.0 (19.5-23.5)  
Perceived general 
health 
      
   excellent/good 5 12.0 (7.5-13.5)  9 10.0 (7.5-12.0)  
   fair 30 11.0 (9.0-16.8) 0.009 31 12.0 (10.0-19.0) 0.001 
   poor 15 17.0 (13.0-21.0)  10 21.0 (16.75-23.5)  
* Kruskal-Wallis test  
Table 16. QLDS scores relating to perceived general health and severity of depression 
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5.4. Clinical performance of the Hungarian QLDS in measuring QoL for patients with 
depression 
The sociodemographic characteristics of the sample and the patient distribution according to 
the depression subtypes are shown in Table 17. Most of the patients were female (71%). The 
mean age was 50.5 years. 
Gender n (%) 
  Male 14 (29) 
  Female 34 (71) 
Age (years)  
  Range 17-80 
  Mean (SD) 50.5 (13.5) 
Marital status n (%) 
  Married 19 (40) 
  Divorced 9 (19) 
  Single 14 (29) 
  Widowed 6 (12) 
Employment status n (%) 
  Employed (full/part-time) 10 (21) 
  Disability pensioner 17 (35) 
  Retired 9 (21) 
  Homemaker 2 (4) 
  Unemployed 7 (15) 
  Student 2 (4) 
Duration of illness (years)  
  Range 0-21 
  Mean (SD) 6.2 (4.97) 
  Median 6.0 
Subtypes of depression n (%) 
  Organic mood disorder 1 (2) 
  Schizoaffective 2 (4) 
  Bipolar affective disorder 2 (4) 
  Unipolar affective disorder 39 (82) 
  Mixed anxiety and depressive disorder 4 (8) 
  
Table 17. Details of the sample 
 
5.4.1. Associations between outcome scores and demographic factors 
No significant difference in QLDS scores was found between the different subtypes of 
depression. The females gave a higher QLDS score at each time, which revealed a poorer 
QoL related to depression. The mean QLDS scores ±SD: malestime 1 = 13.7±6.4; femalestime 1 = 
16.5±5.9; malestime 2 = 10.5±4.5 femalestime 2 = 14.2±9.3. However, these differences did not 
prove significant on the basis of the Mann-Whitney U test (p > 0.05 at each time point). 
 
5.4.2. Associations between psychiatrist-rated severity of depression and self-rated QoL 
The correlations between HAM-D and QLDS and between MADRS and QLDS were 
significant (Table 18). A higher HAM-D or MADRS score, which indicated severe 
depression, was associated with a poorer QoL as assessed by QLDS. The correlation between 
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the psychiatrist-related severity of depression and the different dimensions of the QoL as 
measured by the generic QoL instrument (NHP) was also found to be significant in most cases 
(Table 18). 
 
 Time 1 Time 2 
 HAM-D MADRS HAM-D MADRS 
BDI     0.680**   0.741**     0.659**     0.702** 
QLDS     0.554**   0.550**     0.441**       0.5533** 
NHP distress index     0.425**   0.507**     0.593**     0.668** 
  Energy level    0.310*   0.435**     0.458**     0.493** 
  Pain 0.179   0.3.85* 0.313 0.241 
  Emotional  
  reaction 
    0.477**   0.599**     0.647**     0.775** 
  Sleep 0.284  0.328*     0.464**     0.502** 
  Social isolation     0.390**   0.369**     0.659**     0.741** 
  Physical mobility   0.321* 0.405* 0.332 0.323 
**Spearman correlation significant at the level of 0.01 
*Spearman correlation significant at the level of 0.05  
Table 18. Correlation between psychiatrist-rated severity of depression and patient’s 
perception of HRQoL (QLDS and NHP) and severity of depression (BDI) 
 
The power of the QLDS scores to discriminate between patients with different levels of 
depression severity was good (Table 19). (Kruskal-Wallis test: p > 0.001 at each time point) 
Severe depression was associated with higher QLDS scores, which emphasizes a decreased 
QoL. 
 
 Time 1 Time 2 
 n Median (IQR) p* n Median (IQR) p* 
Severity of depression 
(HAM-D) 
      
  mild 12 10.0 (8.0-13.75)  24 9.5 (8.25-11.0)  
  moderate 3 12.0 (1.0-17.0) 0.001 10 12.5 (8.75-16.25) 0.004 
  severe 28 19.0 (13.5-22.0)  14 16.0 (12.75-21.5)  
* Kruskal-Wallis test  
Table 19. QLDS scores in relation to severity of depression 
 
5.4.3. Clinical improvement and changes in QoL 
An improvement in depression, as measured by the statistical changes in the HAM-D total 
score from the baseline after 4-6 weeks, was significantly correlated with an improvement in 
QLDS (r = 0.588; p < 0.001). The corresponding correlation in terms of MADRS also 
showed a tendency to significance (r = 0.499; p = 0.002).  
75% of the patients achieved remission in the severity of their depression according to the 
MADRS scores, and 73% according to HAM-D, after the 4-5-week follow-up period. 
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5.4.4. Associations between QLDS outcome scores and treatment 
9% of the patients were on TCA (clomipramine) treatment, and 4% on a TCA + SSRI 
combination (Table 20).  Most patients (39%) were on SSRI therapy, and 10% received 
“other” antidepressant (N06AX) besides SSRI. Citalopram was the most preferred drug 
among SSRIs. The most definite change in severity of depression measured by the HAM-D 
score was observed for the SSRI group (median: -10.0). This is in good correlation with the 
changes in QLDS scores (Table 20). 
Patients on some “other” antidepressant (e.g. SNRI, NARI or SSRE) treatment accounted for 
29%. 
Benzodiazepine augmentation was present in 71% of the cases, and the prevalence of 
antipsychotic augmentation was 10%. 
9% of the patients were on benzodiazepine monotherapy; they had not been prescribed any 
antidepressant during the follow-up period studied. 
 
  Time 1 Time2 
 n % Median (IQR) Median (IQR) 
TCA 9 12.5 (11.25-18.25) 18.5 (10.75-46.5) 
TCA + SSRI 4 18.5 (16.0-21.0) 17.0 (16.0-18.0) 
SSRI 39 18.0 (12.0-22.0) 11.0 (8.0-15.0) 
SSRI + „other antidepressant”* 10 9.0 (6.0-26.0) 9.0 (4.0-17.0) 
„Other antidepressant” 29 15.0 (9.75-19.25) 10.5 (8.75-14.5) 
Benzodiazepine 9 13.5 (3.25-20.75) 13.0 (10.75-14.5) 
* „other antidepressant” = N06AX group  
Table 20. QLDS scores in different treatment groups 
 
25% of the patients received supportive psychotherapy besides pharmacotherapy (Table 21). 
At the end of the studied period, significantly lower QLDS scores were observed among the 
patients on supportive psychotherapy, indicating a better QoL (Kruskal-Wallis test, p < 0.05). 
 
 Pharmacotherapy with 
supportive psychotherapy 
Pharmacotherapy without 
supportive psychotherapy 
n (%) 12 (25) 36 (75) 
QLDS median (IQR) 9.0 (7.25-11.75) 13.0 (9.0-18.0)* 
*Kruskal-Wallis test, significant difference, p < 0.05 
  
Table 21. QLDS scores in different therapeutic subgroups 
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6. DISCUSSION 
___________________________________________________________________________ 
 
 
Antidepressant consumption in Hungary exhibited a more than 6-fold increase during the 
period 1993-2006. Not only the volume, but also the structure of antidepressant consumption 
changed considerably: while the sales of TCAs slightly decreased, a marked elevation was 
observed in terms of SSRIs and “other antidepressants”. Similar trends were recorded in 
Ireland, Australia, Italy, Iceland, the Nordic countries, France, Slovenia, Lithuania, Canada 
and Serbia and Montenegro [102-111]. In contrast with these countries, the preferred use of 
TCAs and St. John’s wort over SSRIs has been reported in Germany [112, 113]. 
The international literature suggests, that the dramatic rise in antidepressant consumption in 
the last decade may be related to various factors, including changes in the prevalence of 
depression, consultation and prescription habits, the improved diagnosis and treatment of 
psychiatric patients, changes in the patterns of help-seeking behaviour, the introduction of 
new antidepressants with extensive promotion by drug companies, and the high level of 
reimbursement [2, 103, 105, 109, 114, 115]. 
Population-based data concerning the changes in the prevalence of depression and in the 
number of recognized psychiatric patients are limited in Hungary. An earlier study performed 
by Kopp et al. using the Beck Depression Inventory concluded that the prevalence of 
depression had displayed only a moderate rise in the adult Hungarian population, from 24.3% 
in 1988 to 27.3% in 2002 [116, 117]. The data of the Hungarian Central Statistical Office 
indicated that the number of patients with a diagnosis of depression (on the basis of the ICD-
10 diagnostic criteria system: F30-39) who attended out-patient psychiatric departments 
increased by 28% during the studied period [93]. Further psychiatric service indicators 
suggested that a moderate improvement occurred between 1993 and 2006. The number of out-
patients psychiatric departments rose by 8%, the annual number of new patients taken into 
care by 19%, and the total number of attendances by 53% [93]. It remains unclear whether the 
prevalence of depression really increased or only whether more patients were recognized and 
treated. 
The definition of depression has changed over the years, the criteria for defining depression 
are now wider and the diagnostic methods have become more refined; furthermore, a marked 
change may be experienced in the attitude of society towards psychiatric diseases. These facts 
may account for the increasing number of recognized and treated patients.  
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The introduction of new antidepressants may contribute to the large increase in the 
consumption rate of this drug group. Eleven new substances (110 products) were introduced 
into the Hungarian market during the studied 14-year period [118]. These new antidepressants 
offer a possibility to treat patients with less toxic and more tolerable agents, thereby 
improving the compliance and possibly improving the outcome. 
The increase in overall antidepressant use may also be due to a longer average duration of 
treatment, which is emphasized by the guidelines [119-121]. Additionally, the expanded fields  
of indication of a certain active agent (e.g. posttraumatic stress disorder, insomnia, panic 
disorder, anorexia nervosa, attention deficit disorder and autism) may contribute to the 
observed increased consumption. 
During the studied period, all antidepressant preparations were reimbursed at the 90% or 
100% level by the Hungarian National Health Insurance Fund. We assume that this permanent 
low economic burden on the patients may affect the high level of antidepressant prescription. 
A moderate drop in antidepressant consumption occurred in 2004. This can be explained by 
the fact that the co-payment by patients increased by 64% in the first part of the year, through 
the previous situation was later restored. A similar trend was observed by Poluzzi et al. in 
Italy. Whereas, Italy was traditionally reported as a country with a low prescription of 
antidepressants, the removal of reimbursement restriction was followed by a marked overall 
increase in antidepressant consumption [115]. 
The analysis of regional quantitative differences in antidepressant consumption demonstrated 
a considerable degree of heterogeneity between different parts of Hungary. While the central 
eastern regions were the most prominent antidepressant consumers, the north-eastern regions 
proved to be the lowest consumers. However, the Hungarostudy 2002 reported the highest 
BDI scores in the north-eastern counties. The mean BDI score for these counties was 9.46, 
indicating a higher depression prevalence, and a basically poorer mental health status [122]. 
The above-mentioned discrepancy may point to the problem of the underdiagnosis and 
undertreatment of depression in this region. 
Such regional differences have likewise been reported in Italy, where the interregional 
variations of antidepressant consumption revealed a north-south gradient reflecting industrial 
and economic development [104]. However, in the Italy, not only the volume, but also the 
pattern of antidepressant use differed considerably between the northern and southern regions. 
The increased use of SSRIs was considered one of the parameters of development in the 
north, i.e. an indicator of affluence. 
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My present study also suggested an association between antidepressant use and regional 
economic differences, with positive directions. 
In agreement with earlier studies performed by Laukkala et al [123] and Nakagawa et al 
[124], I found that the unemployment rate and alcohol-abuse disorders are independently 
related to the use of antidepressants in Hungary. However, the unemployment rate 
consistently exhibited a negative, and alcohol consumption consistently a positive correlation 
with the antidepressant use. 
The quantitative differences observed in hospital antidepressant use between the four 
Psychiatric Departments can be partly explained by the various degree of free drug sample 
donation provided by pharmaceutical companies. The pattern of the antidepressant 
consumption in the studied four university-affiliated Psychiatric Departments and in the 
counties was very similar. These results underline my hypothesis that the leading medical 
departments determine the therapeutic modalities in the surrounding areas. 
Without doubt, suicide is one of the most serious consequences of affective disorders. 
Unfortunately, Hungary is still one of the leading countries in the international suicide 
statistics, despite the slightly decreasing tendency in recent years [2]. The causes of suicide 
are complex and multifactorial (sociological, psychological and biological factors have been 
identified as contributors). Mood disorders are regarded as among the most important 
predictors of suicide attempts. This assumption has been confirmed by several studies on the 
Hungarian population. Balázs et al. identified major depressive episodes in 69% of suicide 
victims or suicide attempters [125]. In terms of prevalence data, similar results were found by 
Szadóczky et al. Their results indicated that some kind of affective disorder was present in 
65% of females and 72% of males among patients with a history of suicide attempts. [126]. 
Vörös et al. reached the same conclusion: 60% of suicidal patients had a current depressive 
episode [127]. Zonda et al. also confirmed such results by in an 11-year follow-up study 
[128]. 
In my study, the results of the regional-level data cast doubt on the hypothesis of a simple 
relation between antidepressant consumption and suicide rate. Although significant regional 
variations made the interpretation difficult, I did not find any statistically significant 
correlation between the increased antidepressant consumption and the decreased suicide rate 
at a regional level. 
The relationship between antidepressant consumption and suicide rate is a controversial issue 
in the literature. Many epidemiologic studies have found a reduction of suicidality in regional 
populations in association with increasing antidepressant prescription [129]. The 
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epidemiological study published by Isacsson et al. described an association between the 
greater prescription of antidepressant drugs and the reduced suicide rate in Sweden [130]. 
These findings were extended to other Nordic countries [114, 131]. In agreement with 
Isacsson’s findings, Carlsten et al. reported that the suicide rate in Sweden declined during the 
20 years between 1977 and 1997, but that the rate of decline accelerated after the introduction 
of SSRIs in 1990. [132] A study in Northern Ireland found a statistically significant 
association between the increased antidepressant prescription and a fall in suicide rate in the 
population over 30 years of age [102]. (Unemployment was also inversely associated with 
suicide in this age group.) Ohberg et al. found that suicide mortality declined in Finland 
during the years 1990-1995, and the prescription of SSRIs increased during the same period 
[133]. Hall et al. also came to the conclusion that there seemed to be an association between 
increased antidepressant prescription and the decreased suicide rate in Australia [103]. The 
results of Grunebaum’s study are likewise consistent with the hypothesis that the more 
widespread treatment of depression and the greater use of non-TCAs have contributed to the 
decline in the U.S. suicide rate [134]. The analysis carried out by Morgan et al. in England 
between 1993 and 2002 came to the same conclusion [135]. In Japan, an increase of 1 DDD 
of SSRI use/1000 population/day was associated with a 6% decrease in suicide rate. 
Exploratory analysis suggested a stronger association in males, who experienced a greater 
increase in antidepressant use [124]. 
In contrast, the analysis of long-term trends in suicide, carried out by Guaiana et al. did not 
suggest that increases in antidepressant prescription lie behind the reduction in suicides in 
Italy [136]. This was supported by another Italian study, performed by Barbui et al. [104]. 
Helgason et al. similarly reached the conclusion that the suicide rate was not affected by the 
sales of antidepressants, which have increased 9-fold during the last 20 years in Iceland [105]. 
In contrast to Isacsson’s findings, Reseland et al. found no association between antidepressant 
prescription and suicide rates in the Nordic countries [106]. 
There may be different possible reasons for the discrepancy between the findings of the 
above-mentioned national studies. It may be presumed that various social, cultural and 
economic factors influence the suicide rate. The diverse methodology applied in the various 
studies may be a further reason for these contrary results. Several authors suggest 
concordantly that, despite increasing antidepressant prescription, the underdiagnosis, non-
treatment or undertreatment of depression seem to be the great problems in affective patients 
who have committed suicide [137-143]. This hypothesis may be supported by the present 
study, since there was a trend to a negative association with psychiatric service indicators, 
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though this did not reach the level of statistical significance. Moreover, there was also a trend 
towards a negative association between the suicide rates and a poor economic status in the 
counties. The suicide rate was found to be about 3 times higher in the central and southern 
part of Hungary than in the west, which is generally in a better economic situation. 
A variety of social factors such as unemployment and alcohol abuse have been associated 
with the suicide rate in some [102], but not all studies [114, 124]. My findings suggested that 
changes in unemployment and alcohol consumption rates did not explain the association, 
although alcohol-abuse disorders are a major public health issue in Hungary. 
My present analysis has some limitations. First, I employed ecological analysis rather than a 
patient-based study. Furthermore, the distribution-based antidepressant sales data may 
overestimate the real number of patients on antidepressant treatment. 
The above-mentioned exponential increase in drug consumption experienced in the last 
decade imposes a heavy burden on society. The financial authorities often report that the 
national drug expenditure is very high. Health-care professionals do not agree with this 
general statement, but they accept the fact that there are problems with drug prescription, and 
consumption is sometimes inappropriate. Polypharmacy is also an important issue in the 
international literature. A survey published in 2002 analysed polytherapy among psychiatric 
patients over the last 30 years: the patients participating in the study were from 39 psychiatric 
departments or clinics from the 11 countries involved (n = 23428). The mean number of 
concurrently taken drugs with psychiatric indications in the studied group of patients was 2.2 
before 1980, 2.3 between 1981 and 1990, and 2.9 between 1991 and 2000. This latter was 
significantly higher than the mean number for the period prior to 1980 [144]. The mean 
number of psychiatric drugs taken by the patients involved in my study was similar (2.7) to 
that in the previously mentioned survey. 
The trends of mono and polytherapy among psychiatric patients were also analysed by the 
survey. The frequency of monotherapy significantly decreased: it was 47.8% before 1980, 
31.1% between 1981 and 1990, and 19.6% between 1991 and 2000 [144]. A higher 
monotherapy rate (26%) as regards psychiatric drugs was found by Gaszner et al. in the NIPN 
(National Institute of Psychiatry) in a study performed under the tutelage of the Drug Safety 
Program in Psychiatry (AMSP), 2004 [145]. The drug consumption habits of 952 psychiatric 
inpatients were analysed in 2004.  
In comparison with the above-mentioned data, I found a lower prevalence of monotherapy in 
the studied group at the Psychiatric Department in Szeged (PP group: 5.1%; non-PP group: 
14.5%). 
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Monotherapy should be applied whenever possible, but there are several indications for 
adequate polypharmacy according to the recommendation of the guidelines for the treatment 
of different psychiatric diseases. Mood disorders, which are among the most prevalent 
diagnoses in both groups, can often occur in association with other psychiatric diseases, 
primarily with anxiety disorders. (This trend is reflected by the toplist of drugs used.) The 
treatment of these cases requires concomitant drug use [120, 121]. Furthermore, it should be 
mentioned that the inpatients at the university-affiliated hospitals are the most severe cases. 
They are often considered treatment-resistant and may require combination therapy. 
Augmentation is a frequently applied strategy, especially among those patients who respond 
poorly to the medication. The concomitant use of an antidepressant with levothyroxine or 
lithium is a typical example of augmentation. 
The most popular drug in the PP group was a nootropic agent, piracetam. This can be 
explained by the advanced age in this group and the high frequency of the different types of 
organic, including symptomatic, mental disorders. In these conditions, piracetam is used as an 
adjuvant agent. 
The results of various surveys show that the prevalence of polypharmacy increases with the 
mean age of the patients. The frequency of PP is significantly higher over the age of 65 
[8,9,11]. In one of my previous surveys, in which I analysed the drug utilization of 
traumatology and dermatology patients and patients treated in GP care, the mean age of the 
polypharmacy patients was again found to be over 60 years of age (traumatology: 70 years; 
dermatology: 60; GP: 65) [146]. In the present study, the mean age of the PP group was 61 
years, which is in good agreement with the earlier-published data. 
The female dominance found in my study may result from several factors, e.g. the 
characteristics of the studied patient group, as the ratio of females among psychiatric patients 
is higher. This is supported by the results of OLEF 2000 (National Health Survey) conducted 
by the Health Statistics Unit of the Health Promotion Research Institute [147]: the decrease in 
mental function in all age groups was higher among females (16.3%) than among males 
(8.8%). To study the extent of mental health problems, the GHQ-12 self rating scale (General 
Health Questionnaire) was used in OLEF 2000. Although the GHQ is not appropriate for a 
more specific identification of the nature of the mental decrement and to set up psychiatric 
diagnoses, the results achieved through the GHQ and other additional methods show a good 
correlation, and high scores can indicate the necessity for medical intervention [147]. 
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Demographic surveys show the number of females to be 1.5 times higher than the number of 
males in the age group over 60 years [147]. In my study, the mean age of the PP group was 61 
years, which may partly explain the female dominance.  
Polypharmacy studies indicate that, besides age, the female gender is also an important factor 
predisposing to polypharmacy [11, 148, 149]. This finding correlates well with the present 
study because gender proved to be the second factor predisposing to polypharmacy on the 
basis of the OR values. 
According to certain studies, the prevalence of PP in the total population is 1.2% [11, 149], 
while it is 39% in the elderly population (over the age of 65 years) [148-151]. The most 
commonly used drug groups are those for the treatment of: diseases of the cardiovascular 
system, the central nervous system, the gastrointestinal system, the endocrine system and the 
musculoskeletal system. Besides age, comorbidity is also a major factor contributing to 
polypharmacy [152]. My investigations confirmed this correlation. In the present study, this is 
the most important factor for polypharmacy. 
Cardiovascular diseases are in the leading position for comorbidity [9, 11]. In my previous 
study, the vast majority of the psychiatric, traumatology and dermatology patients and 
patients treated in GP care also suffered from cardiovascular diseases (psychiatry: 68%, 
traumatology: 74%, dermatology: 53%, and GP: 51%) [146]. 
For the treatment of various cardiovascular diseases, e.g. hypertension, the therapeutic 
guidelines currently recommend the use of 2 or 3 drugs in combination rather than 
monotherapy. (Only 25% of patients with hypertension are on monotherapy [11].) 
In conclusion, numerous facts indicate that polypharmacotherapy is necessary in certain 
diseases or when different forms of comorbidity are present. At the same time, it must be 
considered that an increasing number of concurrently used drugs elevates the possibility of 
drug-drug interactions and other unwanted effects. This is particularly so in the elderly 
population, as their pharmacodynamic and pharmacokinetic parameters can differ extremely. 
Consequently, special attention should be paid to the pharmacotherapy of this age group. 
The compliance with treatment regimens is dependent on the impact of that treatment on the 
patients’ well-being. HRQoL improvements due to rational medical interventions recently 
have received increasing attention. Physicians have begun focusing on optimal treatment 
options that also improve the patient’s QoL. This has led to a growing demand for the 
development of valid disease-specific QoL instruments which are applicable to determine the 
outcome of interventions from the patients’ perspective. 
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The development of the Hungarian version of the QLDS followed the standard methodology 
employed in all adaptations of needs-based measures. The application of standard 
methodology is essential to produce high-quality adaptations and to allow data from different 
countries to be combined. The dual panel translation methodology ensured that the translated 
instrument was fully comprehensible for Hungarian-speaking patients. 
Evidence from the field-test interviews indicated that the content of the instrument was 
relevant to the patients and it was well completed by them. The mean time required to 
complete the Hungarian QLDS was less than 10 minutes. This is one advantage of employing 
a depression-specific instrument [16, 153]. 
The Hungarian adaptation of the QLDS has been shown to have excellent psychometric 
properties. The high test-retest correlations indicate an excellent degree of reproducibility, 
with no evidence of excessive random measurement error. The internal consistency of the 
measure was confirmed, with items adequately interrelated. The reliability and internal 
consistency are similar to those of the original English version and other language versions 
(Table 22) [98, 153-155]. 
 
Internal consistency Language version n Test-retest 
reliability Time 1 Time2 
English (original, UK) 74 0.81 0.95 0.94 
Canadian (French) 38 0.96 0.95 0.96 
Canadian (English) 31 0.95 0.95 0.96 
Danish 23 0.89 0.93 0.91 
French 12 0.94 0.89 0.92 
German 18 0.93 0.96 0.93 
Italian 40 0.95 0.96 0.96 
Moroccan 34 0.85 0.88 0.90 
Spanish 27 0.94 0.94 0.93 
US 29 0.82 0.93 0.94 
Hungarian 50 0.89 0.95 0.95 
  
Table 22. Test-retest reliability and internal consistency for new-language versions of the 
QLDS 
 
The association between the scores on the QLDS and the NHP sections confirmed the 
convergent and divergent validity of the new instrument. The correlation coefficients were in 
the expected directions and of the predicted strength. The correlations were higher for those 
sections of the NHP that were most relevant to depression (emotional reactions and social 
isolation). Lower correlations were found between the QLDS and the more physical aspects 
of distress (pain and physical mobility). 
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The QoL would be expected to be sensitive to the general health status as well as to severity 
of depression. The scores on the Hungarian QLDS were clearly related to the perceived 
severity of depression. Similarly to other national versions, these differences in the QLDS 
scores between the perceived severity groups were statistically significant, confirming the 
sensitivity of the instrument (Table 23) [98]. 
 
Self-perceived severity of depression 
Country mild mild/ 
moderate 
moderate moderate/ 
severe 
severe p 
Denmark 4.5   15.0  <0.0001 
France 12.0  15.0  23.0 <0.01 
Germany   14.0   18.5 ns 
Morocco  22.0   29.0 <0.001 
Hungary 
    Time 1 10.5  13.0  21.0 <0.001 
    Time 2 10.0  12.0  21.0 <0.001 
  
Table 23. Median QLDS scores in relation to self-rated severity of depression 
 
Further evidence of the validity of the QLDS was gained by examining the measure’s ability 
to distinguish between groups of patients who differed according to the severity of depression 
as assessed by the BDI (self-rating scale), and the HAM-D or the MADRS (psychiatrist-rating 
scales). 
My findings are consistent with the results of studies which confirmed a significant 
association between the subjective QoL and the clinician-rated psychopathology [76, 98, 
156]. Similar Spearman coefficients were found in these studies designed to assess the 
correlation between the QLDS and the HAM-D scores (rSpearman = 0.61 in the US; rSpearman = 
0.68 in Morocco; rSpearman = 0.43 in Germany; rSpearman = 0.57 in North America; and rSpearman = 
0.39-0.75 in The Netherlands). Only one study (Doraiswamy et al.) reported a weak 
correlation (rSpearman = 0.23) between the satisfaction with life and the clinically assessed 
symptom severity in their study with the same instruments [83]. 
The QLDS scores appeared not to be related to the patient’s gender according to the statistical 
analysis. However, females had a higher score at each time, indicating a poorer HRQoL. 
My results are in agreement with those of other studies that have shown a high degree of 
association between depression and disability [156]. More than one-third of the investigated 
subjects in my study were on a disability pension. 
The results of the present study provide data emphasizing the importance of psychotherapy 
intervention simultaneously with pharmacotherapy as a more efficacious means of improving 
the QoL for depressed patients. 
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Furthermore, I observed that the QLDS promotes a quite precise appraisal of the improvement 
in QoL related to the course of mood. My results suggest that the instrument is sensitive for 
changes in depression symptoms. A clinical improvement in depression rating resulted in an 
improvement in QoL scores. The correlation between the changes in the psychiatrist-
administered depression severity scales (HAM-D and MADRS) and those evaluated with the 
QLDS demonstrated this phenomenon. This finding is consistent with previous reports of the 
sensitivity of the QLDS to changes in depression severity [75, 76, 78, 79, 155, 157]. 
The present study confirmed that the QoL data measured by the QLDS may help in the design 
of appropriate, reliable outcomes for clinical trials and the routine follow-up of depressed 
patients. Self-rating scales can provide important additional information for therapy 
evaluation as they reflect the patient’s personal experience of illness and recovery. 
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7. SUMMARY 
________________________________________________________ 
 
The dramatic increase in the use of antidepressants in the last decade may be related to a 
variety of factors, including a steadily rising prevalence of depression, the improved 
recognition and the treatment of psychiatric patients in Hungary, better safety and tolerability 
of new antidepressants and the high level of reimbursement. The pattern of consumption is 
consistent with the national and international recommendations. 
There are relatively constant and large interregional differences in antidepressant 
consumption and suicide rate in Hungary, which are primarily associated with socio-
economic determinants. The relationship between antidepressant consumption and suicide 
rate is a controversial issue. My results suggest that the marked elevation in antidepressant 
consumption has not had any statistically significant impact on the declining suicide rate at a 
regional level in Hungary. 
At the same time, it should be emphasized, that improved detection, the appropriate treatment 
of depression, and adequate aftercare of persons with a high suicidal risk are the critical 
components of all suicide prevention-strategies. More attention should be given to this 
population, since underdiagnosis and undertreatment still seem to be the most serious 
problems, despite the major increase in the use of antidepressants among patients who have 
attempted suicide 
Depression is associated with considerable decrements in the QoL. Since the compliance with 
medical interventions is largely dependent upon the impact of treatment on a patient’s feelings 
of well-being, stress should be placed on the increasing importance of QoL assessment. 
The adaptation of the QLDS into Hungarian proved successful. The new-language version 
was shown to have excellent psychometric properties. It is regarded as the official Hungarian 
QLDS version by the original authors (Hunt and McKenna). Given the absence of a 
depression-specific QoL instrument in Hungary, the Hungarian QLDS will be a reliable and 
valid outcome measure in clinical and health economic trials as well as in the routine 
monitoring of depressed adult patients. 
QoL measures may provide an adjunct to clinical decisions, widening the lens through which 
patients are viewed and facilitating their input to the treatment process; furthermore, they may 
form a basis for improvements in health care. 
In conclusion, depression should be managed as an important public-health priority to reduce 
disease burden and disability, and to improve the overall health of the population. 
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